NZ504106A - Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them - Google Patents

Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them

Info

Publication number
NZ504106A
NZ504106A NZ504106A NZ50410698A NZ504106A NZ 504106 A NZ504106 A NZ 504106A NZ 504106 A NZ504106 A NZ 504106A NZ 50410698 A NZ50410698 A NZ 50410698A NZ 504106 A NZ504106 A NZ 504106A
Authority
NZ
New Zealand
Prior art keywords
pharmaceutically acceptable
compositions containing
compounds
pipyridine
thiazine
Prior art date
Application number
NZ504106A
Other languages
English (en)
Inventor
Braj Bhushan Lohray
Vidya Bhushan Lohray
Ashok Channaveerappa Bajji
Shivaramayya Kalchar
Rajagopalan Ramanujam
Ranjan Chakrabarti
Original Assignee
Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/085,292 external-priority patent/US6265401B1/en
Application filed by Dr filed Critical Dr
Publication of NZ504106A publication Critical patent/NZ504106A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ504106A 1998-05-27 1998-10-26 Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them NZ504106A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/085,292 US6265401B1 (en) 1997-10-27 1998-05-27 Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
PCT/US1998/022570 WO1999020614A1 (fr) 1998-05-27 1998-10-26 Composes bicycliques, procede de preparation et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
NZ504106A true NZ504106A (en) 2003-02-28

Family

ID=22190649

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ504106A NZ504106A (en) 1998-05-27 1998-10-26 Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them

Country Status (6)

Country Link
EP (1) EP1082313A1 (fr)
JP (1) JP2002507543A (fr)
CN (1) CN100357281C (fr)
NZ (1) NZ504106A (fr)
PL (1) PL341795A1 (fr)
WO (1) WO1999020614A1 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000035437A2 (fr) * 1998-12-17 2000-06-22 Mindset Biopharmaceuticals (Usa), Inc. Utilisation accrue de glucose par le cerveau
US6528507B1 (en) 1999-04-16 2003-03-04 Dr. Reddy's Laboratories Limited Polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
AU3957800A (en) * 1999-04-16 2000-11-02 Dr. Reddy's Research Foundation Crystalline r- guanidines, arginine or (l) -arginine (2(s)) -2- ethoxy -3-(4- (2-(10(h) -phenoxazin -10-yl)ethoxy}phenyl)propanoate
TR200103851T2 (tr) * 1999-04-16 2002-04-22 Dr. Reddy' S Research Foundation Bir antidiyabetik maddenin yeni polimorfik formları, bunların hazırlanması için işlem ve bunları farmasötik bileşimler
JP2002542237A (ja) * 1999-04-20 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 新規な化合物、それらの製造及び使用
CZ20013558A3 (cs) * 1999-04-20 2002-05-15 Novo Nordisk A/S Sloučenina, farmaceutický prostředek, způsob léčby, jejich příprava a vyuľití
US6369055B1 (en) 1999-04-20 2002-04-09 Novo Nordisk A/S Compounds, their preparation and use
EP1171438A1 (fr) 1999-04-20 2002-01-16 Novo Nordisk A/S Composes, preparation et utilisation associees
US6972294B1 (en) 1999-04-20 2005-12-06 Novo Nordisk, A/S Compounds, their preparation and use
MXPA01010916A (es) * 1999-04-28 2002-06-21 Reddy Research Foundation Heterociclos biciclicos sustituidos, procedimiento para su preparacion y su uso como agentes contra la obesidad y como agentes hipocolesterolemicos.
AP1522A (en) * 2000-01-19 2005-12-22 Cadila Healthcare Ltd Compounds having hypolipedemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them.
US6555577B1 (en) 2000-01-28 2003-04-29 Novo Nordisk A/S Compounds, their preparation and use
US6569901B2 (en) 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
PL357010A1 (en) * 2000-01-28 2004-07-12 Novo Nordisk A/S Propionic acid derivatives and their use in the treatment of diabetes and obesity
US6908908B2 (en) 2000-05-12 2005-06-21 Ortho-Mcneil Pharmaceutical, Inc. Biologically active 4H-benzo [1,4] oxazin-3-ones
EP1280784B1 (fr) * 2000-05-12 2007-06-27 Ortho-McNeil Pharmaceutical, Inc. 4h-benzo 1,4|oxazine-3-ones biologiquement actives
AU2001261503A1 (en) * 2000-05-12 2001-11-26 Ortho-Mcneil Pharmaceutical, Inc. Methods of treatment using benzoxazinones as peroxisome proliferator activated receptor gamma modulators
US6599899B2 (en) 2000-05-12 2003-07-29 Ortho-Mcneil Pharmaceutical, Inc. Benzoxazinones as peroxisome proliferator activated receptor gamma modulators and method of treatment
AU2001284335A1 (en) * 2000-09-04 2002-03-22 Dr. Reddy's Research Foundation Process for the preparation of 2-(3,4-dihydro-1,4-benzothiazin-4-yl)ethylmethane sulphonate
AU2002212672A1 (en) * 2000-10-12 2002-04-22 Dr. Reddy's Research Foundation Salts of benzothiazine and benzoxazine derivatives and pharmaceutical compositions containing them
US20020198202A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and an antilipemic agent
WO2003006022A1 (fr) * 2001-07-09 2003-01-23 Dr. Reddy's Laboratories Ltd. Derives de tetrahydroquinoline et leur utilisation en medecine, procede de preparation associe et compositions pharmaceutiques contenant lesdits composes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
PL369732A1 (en) 2001-10-16 2005-05-02 Dr.Reddy's Laboratories Ltd. Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them
JP2005518408A (ja) 2001-12-29 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ 異常脂肪血症を治療するための、ｇｌｐ−１化合物と他の薬物との組み合わせ使用
WO2003099800A1 (fr) * 2002-05-23 2003-12-04 Dr. Reddy's Laboratories Limited Procede ameliore pour la preparation d'agents antidiabetiques bicycliques
EP1734963A4 (fr) 2004-04-02 2008-06-18 Merck & Co Inc Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
EP3241839B1 (fr) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
SG191772A1 (en) 2011-01-31 2013-08-30 Cadila Healthcare Ltd Treatment for lipodystrophy
CN105001219A (zh) 2011-02-25 2015-10-28 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
US20150004144A1 (en) 2011-12-02 2015-01-01 The General Hospital Corporation Differentiation into brown adipocytes
KR20150036245A (ko) 2012-08-02 2015-04-07 머크 샤프 앤드 돔 코포레이션 항당뇨병 트리시클릭 화합물
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
EP2970119B1 (fr) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
WO2014151206A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
MA38385A1 (fr) 2013-04-22 2017-09-29 Cadila Healthcare Ltd Nouvelle composition pour la stéatose hépatique non alcoolique (nafld)
WO2014195967A2 (fr) 2013-05-30 2014-12-11 Cadila Healthcare Limited Procédé de préparation de pyrroles présentant des activités hypocholestérolémiques hypolipidémiques
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (fr) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
WO2015033357A2 (fr) 2013-09-06 2015-03-12 Cadila Healthcare Limited Procédé amélioré de préparation de dérivés de pyrrole
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018104916A1 (fr) 2016-12-09 2018-06-14 Cadila Healthcare Limited Traitement de la cholangite biliaire primitive
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN110092774B (zh) * 2018-01-29 2022-04-08 中国科学院上海药物研究所 芳香丙酸类衍生物、及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173350B1 (da) * 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
US5496815A (en) * 1990-02-08 1996-03-05 Tanabe Seiyaku Co., Ltd. Thiazine (or oxazine) derivatives and preparation thereof
CA2035147A1 (fr) * 1990-02-08 1991-08-09 Kousuke Yasuda Derives de la thiazine (ou de l'oxazine) et leur preparation
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
JPH05194236A (ja) * 1991-07-25 1993-08-03 Tanabe Seiyaku Co Ltd 中枢性カルシウム拮抗剤
WO1996004261A1 (fr) * 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxoazoles et derives de pryridine destines a etre utilises pour le traitement du diabete tardif
JPH0912575A (ja) * 1995-06-28 1997-01-14 Sankyo Co Ltd ベンゾオキサジンおよびベンゾチアジン誘導体

Also Published As

Publication number Publication date
CN100357281C (zh) 2007-12-26
JP2002507543A (ja) 2002-03-12
EP1082313A1 (fr) 2001-03-14
WO1999020614A1 (fr) 1999-04-29
PL341795A1 (en) 2001-05-07
CN1281443A (zh) 2001-01-24

Similar Documents

Publication Publication Date Title
NZ504106A (en) Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them
MY121760A (en) Benzothiazin and benzoxazin derivatives;their preparation and uses
WO1999008501A3 (fr) Nouveaux composes heterocycliques, leur utilisation en medecine, leur procede de preparation et compositions pharmaceutiques les contenant
YU60701A (sh) Nova triciklička jedinjenja i njihova upotreba u medicini; postupak za njihovo pripremanje i farmaceutske kompozicije koje ih sadrže
IL127296A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
MY140057A (en) Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine
CA2258949A1 (fr) Nouveaux composes heterocycliques, leur procede de preparation, compositions pharmaceutiques les contenant et utilisation de ces composes dans le traitement du diabete et des maladies associees
MXPA04005257A (es) Esteres y amidas como agonistas ppar-alfa.
AU6966498A (en) Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypol ipidaemic and antihypertensive properties
MXPA02012033A (es) Derivados de 2-aminocarbonil-9h-purina.
YU75101A (sh) Supstituisani biciklični heterocikli, postupak njihove izrade i njihova upotreba kao antigojaznih i hipoholesterolemijskih agenasa
MXPA03000161A (es) Compuestos novedosos los cuales tienen actividad antiinflamatoria, proceso para su preparacion y composiciones farmaceuticas que las contienen.
YU52403A (sh) Heterociklična jedinjenja koja imaju antibakterijsko dejstvo, postupak za njihovo dobijanje i farmaceutske smeše koje ih sadrže
BG106932A (en) Novel compounds having hypolipedemic and hypocholesteremic activities, processes for their preparation and pharmaceutical compositions containing them
NZ216048A (en) Quinolylglycinamide derivatives, and pharmaceutical compositions containing such
NZ210100A (en) 5h,11h-pyrrolo(2,1-c)(1,4)benzoxazepine derivatives and pharmaceutical compositons
UA72883C2 (uk) Біциклічна сполука, способи її одержання, фармацевтичні композиції, що її містять,способи лікування та попередження різних захворювань, проміжні сполуки та способи їх одержання
YU76500A (sh) Hemijska sinzeza morfolinskih derivata
CA2307068A1 (fr) Composes bicycliques, procede de preparation et compositions pharmaceutiques les contenant
AU7109798A (en) Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypol ipidemia and antihypertensive properties
MXPA04002784A (es) Sales farmaceuticamente aceptables de 20(s)-camptotecinas.
MY131832A (en) New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
RS32404A (en) Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them
AU6663596A (en) One pot synthesis of 2-oxazolidinone derivatives
ES2103237A1 (es) Nuevo compuesto derivado del cromeno

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: DR. REDDY S LABORATORIES LIMITED, IN

Free format text: OLD OWNER(S): REDDY-CHEMINOR, INC.; DR. REDDY S RESEARCH FOUNDATION

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)